Side-by-side comparison of AI visibility scores, market position, and capabilities
Meta's standalone VR headset line with Quest 3 ($499) and Quest 3S ($299) mixed reality; $40B+ invested in Reality Labs competing with PlayStation VR2 and Apple Vision Pro for the XR platform.
Meta Quest is Meta Platforms' (NASDAQ: META) standalone virtual reality headset line — the Quest 3 (launched October 2023, $499 for 128GB) and Quest 3S (launched October 2024, $299) offering mixed reality (color passthrough that blends virtual content with the real world), inside-out tracking (no external sensors), and access to the Meta Quest Store with 500+ apps spanning gaming, fitness, social VR, and enterprise applications. Meta has invested over $40 billion in Reality Labs (its metaverse/VR/AR division) since 2019, generating approximately $2 billion in annual Quest hardware and software revenue while posting multi-billion-dollar annual operating losses in the division.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.